CompletedPhase 3NCT01581593
Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)
Studying Agammaglobulinemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Kedrion S.p.A.
- Principal Investigator
- Mirella Calcinai, MDKedrion SpA
- Intervention
- Kedrion IVIG 10%(biological)
- Enrollment
- 45 enrolled
- Eligibility
- 2-70 years · All sexes
- Timeline
- 2012 – 2014
Study locations (15)
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Allergy Associates of the Palm Beaches, North Palm Beach, Florida, United States
- Family Allergy & Asthma Center, PC, Atlanta, Georgia, United States
- Rush University, Chicago, Illinois, United States
- University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
- Midwest Immunology Clinic, Plymouth, Minnesota, United States
- AAIR Research Center, Rochester, New York, United States
- Optimed Research, LTD, Columbus, Ohio, United States
- Dallas Allergy Immunology Research, Dallas, Texas, United States
- AARA Research Center, Dallas, Texas, United States
- Virginia Commonwealth University Health Systems, Richmond, Virginia, United States
- Marycliff Allergy Specialists, Spokane, Washington, United States
- Gordon Sussman Clinical Research Inc., Toronto, Ontario, Canada
- Pediatric & Adult Allergy & Clinical Immunology, Toronto, Ontario, Canada
- The Hospital for Sick Children, Toronto, Ontario, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01581593 on ClinicalTrials.govOther trials for Agammaglobulinemia
Additional recruiting or active studies for the same condition.